Cargando…
Cardiometabolic effects of a novel SIRT1 activator, SRT2104, in people with type 2 diabetes mellitus
BACKGROUND: The cardiometabolic effects of SRT2104, a novel SIRT1 activator, were investigated in people with type 2 diabetes mellitus (T2DM). METHODS: Fifteen adults with T2DM underwent a randomised, double-blind, placebo-controlled cross-over trial and received 28 days of oral SRT2104 (2.0 g/day)...
Autores principales: | Noh, Radzi M, Venkatasubramanian, Sowmya, Daga, Shruti, Langrish, Jeremy, Mills, Nicholas L, Lang, Ninian N, Hoffmann, Ethan, Waterhouse, Brian, Newby, David E, Frier, Brian M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5588958/ https://www.ncbi.nlm.nih.gov/pubmed/28912956 http://dx.doi.org/10.1136/openhrt-2017-000647 |
Ejemplares similares
-
Effects of the small molecule SIRT1 activator, SRT2104 on arterial stiffness in otherwise healthy cigarette smokers and subjects with type 2 diabetes mellitus
por: Venkatasubramanian, Sowmya, et al.
Publicado: (2016) -
Cardiovascular Effects of a Novel SIRT1 Activator, SRT2104, in Otherwise Healthy Cigarette Smokers
por: Venkatasubramanian, Sowmya, et al.
Publicado: (2013) -
Neuroprotection of SRT2104 in Murine Ischemia/Reperfusion Injury Through the Enhancement of Sirt1-Mediated Deacetylation
por: Bai, Xue, et al.
Publicado: (2023) -
Assessing Colonic Exposure, Safety, and Clinical Activity of SRT2104, a Novel Oral SIRT1 Activator, in Patients with Mild to Moderate Ulcerative Colitis
por: Sands, Bruce E., et al.
Publicado: (2015) -
Sirtuin 1 activator SRT2104 protects Huntington's disease mice
por: Jiang, Mali, et al.
Publicado: (2014)